A defining moment in first-line maintenance therapy:

For patients with gBRCA-mutated* metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of first-line platinum-based chemotherapy1

Not an actual patient.

POLO trial in gBRCA-mutated metastatic pancreatic cancer

mPFS

7.4

MONTHS

Primary endpoint

Progression-free Survival:

HR=0.53 (95% CI: 0.35-0.81); P=0.0035

LYNPARZA nearly doubled median PFS versus placebo (7.4 months vs 3.8 months)1

Explore the efficacy data
Image of DNA

TEST

for gBRCAm

at diagnosis of mPaC

Learn about testing

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Pancreatic Adenocarcinoma

Olaparib is included as a Category 2A† preferred option for maintenance therapy for patients with germline BRCA1/2-mutated metastatic adenocarcinoma of the pancreas, and no disease progression following first-line platinum-based chemotherapy for at least 16 weeks.2

NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

†Category 2A: Based upon lower-level evidence, there is uniform NCCN consensus (≥85% support of the Panel) that the intervention is appropriate.

The

ONLY FDA-approved

PARP inhibitor

for first-line maintenance therapy in gBRCA-mutated* metastatic pancreatic cancer1,3-6

Dedicated to patient care1

Initial approval of LYNPARZA in 2014.1
Initial approval of pancreatic cancer indication in 2019.7